POINT Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- POINT Biopharma's estimated annual revenue is currently $31.6M per year.
- POINT Biopharma's estimated revenue per employee is $155,000
Employee Data
- POINT Biopharma has 204 Employees.
- POINT Biopharma grew their employee count by 40% last year.
POINT Biopharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | EVP, Commercial | Reveal Email/Phone |
3 | EVP Clinical Development | Reveal Email/Phone |
4 | EVP - US Manufacturing Operations | Reveal Email/Phone |
5 | EVP Regulatory Affairs | Reveal Email/Phone |
6 | VP, Discovery and Translational Sciences | Reveal Email/Phone |
7 | EVP Regulatory Affairs | Reveal Email/Phone |
8 | Director, Clinical Science | Reveal Email/Phone |
9 | Manager Information Technology | Reveal Email/Phone |
10 | QC Analyst | Reveal Email/Phone |
POINT Biopharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.7M | 9 | -72% | $39.4M | N/A |
#2 | $0.9M | 11 | -83% | $23.8M | N/A |
#3 | $87.6M | 565 | 6% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $7.8M | 50 | -68% | N/A | N/A |
#6 | $13.5M | 87 | 30% | N/A | N/A |
#7 | $17.8M | 115 | -6% | N/A | N/A |
#8 | $0.9M | 11 | -39% | N/A | N/A |
#9 | $13.6M | 88 | -20% | $86M | N/A |
#10 | $20M | 129 | -12% | N/A | N/A |
What Is POINT Biopharma?
POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer
keywords:N/A
N/A
Total Funding
204
Number of Employees
$31.6M
Revenue (est)
40%
Employee Growth %
N/A
Valuation
N/A
Accelerator
POINT Biopharma News
2022-04-20 - First European Union Patient Dosed with 177Lu-PNT2002 in ...
POINT Biopharma's Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US,...
2022-04-06 - POINT Biopharma to Present on its Pan-Cancer FAP-Alpha ...
INDIANAPOLIS, April 11, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the Company or POINT),...
2022-03-22 - PLUVICTO's approval mounts pressure on POINT ...
PLUVICTO's FDA approval extends pressure on POINT Biopharma's rival targeted radioligand therapy, PSMA [Lu-177]-PNT2002, whose estimated...
Other Companies in Toronto
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $32.5M | 204 | 7% | N/A |
#2 | $7.5M | 204 | -66% | N/A |
#3 | $39M | 204 | -5% | N/A |
#4 | $7.5M | 204 | 38% | N/A |
#5 | $32.5M | 204 | 41% | N/A |